Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1No longer available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Neoplasms 3Solid Tumours 2Multiple Myeloma 2Lymphoma 2Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neuroblastoma 1Myelodysplastic Syndromes 1Metastatic NUT Carcinoma 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma 1Breast Neoplasms 1

Interventions

AZD 6244 5GSK 1363089 3molibresib 2pazopanib 1ispinesib 1enzalutamide 1brigimadlin 1abiraterone 1Topotecan 1SLC-0111 1Rifampin 1Prednisone 1Omeprazole 1Moxifloxacin 1Midazolam 1Itraconazole 1Granisetron 1Fluconazole 1Famotidine 1Doxorubicin 1Cytochrome P-450 CYP3A 1Cytochrome P-450 CYP2C19 1Cytochrome P-450 CYP1A2 1Carboplatin 1Carbon-14 1Caffeine 1CH5183284 1BGC945 12-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Solid Tumours × molibresib × Clear all
NCT03150056 2022-08-10

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

GlaxoSmithKline

Phase 1 Terminated
73 enrolled 34 charts
Other solid neoplasm

Solid Tumours

NCT03702036 2020-04-13

Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma

GlaxoSmithKline

No longer available
Other solid neoplasm

Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡